Expertise in
8
conditions

Dr. Saravut Weroha

Hematology | Oncology
Mayo Clinic Cancer Center
200 1st St Sw, 
Rochester, MN 
Accepting New Patients
Offers Telehealth
Expertise in
8
conditions
Mayo Clinic Cancer Center
200 1st St Sw, 
Rochester, MN 

Overview

Saravut Weroha is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota.

Dr. Weroha is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, Desmoplastic Small Round Cell Tumor, and Salpingo-Oophorectomy.

He is actively involved in clinical research, co-authoring 96 peer reviewed articles and participating in 5 clinical trials. Dr. Weroha is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in MN

Hospital Affiliations

Mayo Clinic Health System - Cannon Falls
Mayo Clinic Health System In Red Wing
Mayo Clinic Hospital Rochester

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthPartners
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Mayo Clinic Cancer Center
200 1st St Sw, Rochester, MN 55905
Other Locations
MN - Cancer
200 1st St SW, Rochester, MN 55905

Additional Areas of Focus

Dr. Weroha has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum
A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: December 23, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole
Study Phase: Phase 2
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers
Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers
Enrollment Status: Completed
Publish Date: December 05, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Phase 2 Trial of Ribociclib (LEE011) and Letrozole in ER Positive Relapsed Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinomas, and Endometrial Cancers.
A Phase 2 Trial of Ribociclib (LEE011) and Letrozole in ER Positive Relapsed Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinomas, and Endometrial Cancers.
Enrollment Status: Completed
Publish Date: October 26, 2021
Intervention Type: Drug, Other
Study Drugs: Letrozole, Ribociclib
Study Phase: Phase 2
View 3 Less Clinical Trials

95 Total Publications

Factors affecting trainees' preferred timing of clinical clerkships during MD-PhD training.
Factors affecting trainees' preferred timing of clinical clerkships during MD-PhD training.
Journal: medRxiv : the preprint server for health sciences
Published: May 25, 2026
Similar Doctors
Expertise in
25
conditions
Dr. Stephen M. Ansell
Hematology | Oncology
Expertise in
25
conditions
Dr. Stephen M. Ansell
Hematology | Oncology
Referral may be required

MN - Cancer

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-923-2592
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stephen Ansell is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota. Dr. Ansell is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy. Dr. Ansell is currently accepting new patients.

Expertise in
43
conditions
Dr. Ronald S. Go
Hematology | Oncology
Expertise in
43
conditions
Dr. Ronald S. Go
Hematology | Oncology
Referral may be required

MN - Cancer

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-512-1667
Languages Spoken:
English, Filipino, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Ronald Go is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota. Dr. Go is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Rosai-Dorfman Disease, Histiocytosis, Reticulohistiocytoma, Bone Marrow Transplant, and Splenectomy. Dr. Go is currently accepting new patients.

Expertise in
11
conditions
Dr. Francis K. Buadi
Hematology | Oncology
Expertise in
11
conditions
Dr. Francis K. Buadi
Hematology | Oncology
Referral may be required

MN - Cancer Transplant

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-910-0296
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Francis Buadi is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota. Dr. Buadi is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Smoldering Multiple Myeloma, POEMS Syndrome, and Bone Marrow Transplant. Dr. Buadi is currently accepting new patients.

Frequently Asked Questions about Dr. Saravut Weroha

How do I make an appointment with Dr. Saravut Weroha?

You can book an appointment with Dr. Saravut Weroha by calling their office at 507-512-1667. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Saravut Weroha a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Saravut Weroha is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Saravut Weroha specialize in?

While Dr. Saravut Weroha is a Hematology, they have specific expertise in Ovarian Cancer, Ovarian Carcinosarcoma, and Virilizing Ovarian Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Saravut Weroha participate in research or clinical trials?

Yes. Dr. Saravut Weroha has published 95 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Saravut Weroha's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Saravut Weroha accept my insurance?

Dr. Saravut Weroha accepts most major insurance plans, including Blue Cross Blue Shield and Cigna. We recommend calling the office directly at 507-512-1667 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weroha's expertise for a condition
ConditionClose
View All 39 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile